Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Jeremy Monfray, CRA, Hélène Labussière-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 2542.

https://doi.org/10.1182/blood.V124.21.2542.2542

Published: 2014

Journal Articles

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3892.

https://doi.org/10.1182/blood.V124.21.3892.3892

Published: 2014

Journal Articles

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Mohamed Elhamri, PhD, Jeremy Monfray, CRA, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Adriana Plesa, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3691.

https://doi.org/10.1182/blood.V124.21.3691.3691

Published: 2014

Journal Articles

Comparison Of BCR-ABL1/ABL1 and BCR-ABL1/GUS Ratios At Different Clinical Decision Cut-Offs In Chronic Phase Chronic Myelogenous Leukemia Patients On Imatinib

Sarah Huet, Denis Souche, Jean-Pierre Magaud, Pascale Cony-Makhoul, MD, Yann Guillermin, MD, Mael Heiblig, MD, Mauricette Michallet, MD, PhD, Franck E. Nicolini, MD, PhD, Sandrine Hayette, PhD

Blood (2013) 122 (21): 2713.

https://doi.org/10.1182/blood.V122.21.2713.2713

Published: 2013

Journal Articles

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Helene Labussiere, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Sophie Ducastelle, MD, Xavier Thomas, MD

Blood (2013) 122 (21): 2721.

https://doi.org/10.1182/blood.V122.21.2721.2721

Published: 2013

Journal Articles

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed El Hamri, PhD, Lila Gilis, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD, PhD, Xavier Thomas, MD

Blood (2013) 122 (21): 2162.

https://doi.org/10.1182/blood.V122.21.2162.2162

Published: 2013

Journal Articles

Reappraisal Of The p16 INK4A /Prb Pathway and Telomerase Activity, Markers Of Cell Activation and Aging, In Adult Acute Lymphoblastic Leukemia: A Graall Study

Blood (2013) 122 (21): 2579.

https://doi.org/10.1182/blood.V122.21.2579.2579

Published: 2013

Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD

Blood (2011) 118 (21): 1684.

https://doi.org/10.1182/blood.V118.21.1684.1684

Published: 2011

Journal Articles

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Madeleine Etienne, CRA, Elodie Gadolet, CRA, Helene Labussiere, MD, Sandrine Hayette, PhD, Franck E. Nicolini, MD, PhD

Blood (2011) 118 (21): 1691.

https://doi.org/10.1182/blood.V118.21.1691.1691

Published: 2011

Journal Articles

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

Blood (2011) 118 (21): 2535.

https://doi.org/10.1182/blood.V118.21.2535.2535

Published: 2011

Journal Articles

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Lila Gilis, MD, Madeleine Etienne, CRA, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Helene Labussiere, MD, Luc Gerland, MD, Damien Waz, MStud, Mohamad Sobh, Pharm., M, Stephane Morisset, Stat., Mauricette Michallet

Blood (2010) 116 (21): 3407.

https://doi.org/10.1182/blood.V116.21.3407.3407

Published: 2010

Journal Articles

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Blood (2010) 116 (21): 3410.

https://doi.org/10.1182/blood.V116.21.3410.3410

Published: 2010

Journal Articles

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Benedicte Deau, MD, Mathias Montveneur, MStud, Valérie Coiteux, MD, Aline Renneville, MD, Francoise Rigal-Huguet, MD, Eric Delabesse, MD, PhD, Michel Tulliez, MD, Dominique Bories, MD, PhD, Aude Charbonnier, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Thibault Legay, MD, Eric Lippert, PhD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Jean-Michel Cayuela, PhD, Shanti Amé, MD, Marie-Pierre Gaub, MD, Martine Gardembas, MD, Odile Blanchet, MD, Bruno Audhuy, MD, Agnès Buzyn, MD, PhD, Elisabeth Mac Intyre, MD, PhD, Anna-Lisa Andreoli, MD, Oumedaly Reman, Nathalie Contentin, MD, Christian Bastard, MD, Jean-Christophe Ianotto, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Said Brahimi, MD, Viviane Dubruille, Jean-Francois Brantus, MD, Mohamad Sobh, Pharm., M., Stephane Morisset, Stat., Claude Preudhomme, MD, PhD, Sandrine Hayette, PhD, Franck E Nicolini, MD, PhD

Blood (2010) 116 (21): 3378.

https://doi.org/10.1182/blood.V116.21.3378.3378

Published: 2010

Journal Articles

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Franck Nicolini, MD, PhD, Laurence Legros, MD, PhD, Lydia Roy, MD, PhD, Jean-Claude Chomel, MD, Kaddour Chabane, BSc, Sophie Ducastelle, MD, Selim Corm, MD, Mauricette Michallet, MD, PhD, Francois Guilhot, MD, Ali Turhan, MD, PhD, Sandrine Hayette, PhD

Blood (2008) 112 (11): 1103.

https://doi.org/10.1182/blood.V112.11.1103.1103

Published: 2008

Journal Articles

Detection of Twelve Nucleotides Instertion in the BCR-ABL Kinase Domain in an Imatinib-Resistant but Dasatinib-Sensitive Patient with Bi-Phenotypic Acute Leukemia.

Sandrine Hayette, PhD, Kaddour Chabane, BSc, Andrei Tchirkov, MD, PhD, Marc G Berger, MD, PhD, jean-Pierre Magaud, MD, PhD, Franck E Nicolini, MD, PhD, Olivier Tournilhac, MD, PhD

Blood (2008) 112 (11): 1615.

https://doi.org/10.1182/blood.V112.11.1615.1615

Published: 2008

NARROW

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Comparison Of BCR-ABL1/ABL1 and BCR-ABL1/GUS Ratios At Different Clinical Decision Cut-Offs In Chronic Phase Chronic Myelogenous Leukemia Patients On Imatinib

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Reappraisal Of The p16 INK4A /Prb Pathway and Telomerase Activity, Markers Of Cell Activation and Aging, In Adult Acute Lymphoblastic Leukemia: A Graall Study

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABL T315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

Detection of Twelve Nucleotides Instertion in the BCR-ABL Kinase Domain in an Imatinib-Resistant but Dasatinib-Sensitive Patient with Bi-Phenotypic Acute Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only